Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

Krause, 2005, Tyrosine kinases as targets for cancer therapy, N Engl J Med, 353, 172, 10.1056/NEJMra044389 Ellis, 2008, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat Rev Cancer, 8, 579, 10.1038/nrc2403 Force, 2007, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition, Nat Rev Cancer, 7, 332, 10.1038/nrc2106 Chu, 2007, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet, 370, 2011, 10.1016/S0140-6736(07)61865-0 Kerkelä, 2006, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nat Med, 12, 908, 10.1038/nm1446 Khakoo, 2008, Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor, Cancer, 112, 2500, 10.1002/cncr.23460 Hutson, 2008, Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies, Oncologist, 13, 1084, 10.1634/theoncologist.2008-0120 Schmidinger, 2008, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 26, 5204, 10.1200/JCO.2007.15.6331 Strevel, 2007, Molecularly targeted oncology therapeutics and prolongation of the QT interval, J Clin Oncol, 25, 3362, 10.1200/JCO.2006.09.6925 Ederhy, 2009, QT interval prolongation among patients treated with angiogenesis inhibitors, Target Oncol, 4, 89, 10.1007/s11523-009-0111-3 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Romond, 2000, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Verheul, 2007, Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat Rev Cancer, 7, 475, 10.1038/nrc2152 Sane, 2004, Angiogenic growth factors and hypertension, Angiogenesis, 7, 193, 10.1007/s10456-004-2699-3 Veronese, 2006, Mechanisms of hypertension associated with BAY 43-9006, J Clin Oncol, 24, 1363, 10.1200/JCO.2005.02.0503 Tam, 2004, Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies, Am J Hematol, 77, 72, 10.1002/ajh.20147 Ozcan, 2006, Reversible posterior leukoencephalopathy syndrome and bevacizumab, N Engl J Med, 354, 980, 10.1056/NEJMc052954 Glusker, 2006, Reversible posterior leukoencephalopathy syndrome and bevacizumab, N Engl J Med, 354, 980, 10.1056/NEJMc052954 Govindarajan, 2006, Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006, J Clin Oncol, 24, e48, 10.1200/JCO.2006.08.4608 Hariawala, 1996, VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts, J Surg Res, 63, 77, 10.1006/jsre.1996.0226 Li, 2002, KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF, Hypertension, 39, 1095, 10.1161/01.HYP.0000018588.56950.7A Eppler, 2002, A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans, Clin Pharmacol Ther, 72, 20, 10.1067/mcp.2002.126179 Ciuffetti, 2003, Capillary rarefaction and abnormal cardiovascular reactivity in hypertension, J Hypertens, 21, 2297, 10.1097/00004872-200312000-00018 Mourad, 2008, Blood pressure rise following angiogenesis inhibition by bevacizumab. a crucial role for microcirculation, Ann Oncol, 19, 927, 10.1093/annonc/mdm550 Jessup, 2009, Circulation, 119, 1977, 10.1161/CIRCULATIONAHA.109.192064 Izzedine, 2009, Management of hypertension in angiogenesis inhibitor-treated patients, Ann Oncol, 20, 807, 10.1093/annonc/mdn713 Mancia, 2005, European society of hypertension European society of cardiology: joint national committee VII and European society of hypertension/European society of cardiology guidelines for evaluating and treating hypertension, J Am Soc Nephrol, 16, S74, 10.1681/ASN.2004110963 Fonseca, 2004, Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care, Eur J Heart Fail, 6, 813, 10.1016/j.ejheart.2004.08.003 Fonseca, 2004, The diagnosis of heart failure in primary care: value of symptoms and signs, Eur J Heart Fail, 6, 795, 10.1016/j.ejheart.2004.08.002 Fonseca, 2006, Diagnosis of heart failure in primary care, Heart Fail Rev, 11, 95, 10.1007/s10741-006-9481-0 Thomas, 2002, Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure, Am J Med, 112, 437, 10.1016/S0002-9343(02)01048-3 Fromme, 2004, How accurate is clinician reporting of chemotherapy adverse effects? a comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30, J Clin Oncol, 22, 3485, 10.1200/JCO.2004.03.025 Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233 Burjonroppa, 2007, Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload, Am J Clin Oncol, 30, 287, 10.1097/01.coc.0000256101.04404.b0 Popat, 2008, Therapy insight: anthracyclines and trastuzumab – the optimal management of cardiotoxic side effects, Nat Clin Pract Oncol, 5, 324, 10.1038/ncponc1090 Viani, 2007, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials, BMC Cancer, 7, 153, 10.1186/1471-2407-7-153 Atallah, 2007, Congestive heart failure is a rare event in patients receiving imatinib therapy, Blood, 110, 1233, 10.1182/blood-2007-01-070144 Verweij, 2007, Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005, Eur J Cancer, 43, 974, 10.1016/j.ejca.2007.01.018 Paul, 2004, Tyrosine kinase – role and significance in Cancer, Int J Med Sci, 1, 101, 10.7150/ijms.1.101 Boyce, 2005, A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress, Science, 307, 935, 10.1126/science.1101902 Pattacini, 2004, Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase, Leuk Res, 28, 191, 10.1016/S0145-2126(03)00218-2 Hantschel, 2008, Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib, Leuk Lymphoma, 49, 615, 10.1080/10428190801896103 Quintás-Cardama, 2007, Flying under the radar: the new wave of BCR-ABL inhibitors, Nat Rev Drug Discov, 6, 834, 10.1038/nrd2324 Fernández, 2007, An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic, J Clin Invest, 117, 4044, 10.1172/JCI32373 Perez, 2008, Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials, Mayo Clin Proc, 83, 679, 10.4065/83.6.679 Guarneri, 2006, Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D Anderson Cancer Center experience, J Clin Oncol, 24, 4107, 10.1200/JCO.2005.04.9551 Ewer, 2005, Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment, J Clin Oncol, 23, 7820, 10.1200/JCO.2005.13.300 Demetri, 2006, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 368, 1329, 10.1016/S0140-6736(06)69446-4 Motzer, 2007, Sunitinib versus interferon in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Telli, 2008, Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate, Ann Oncol, 19, 1613, 10.1093/annonc/mdn168 Jones, 2009, Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring, Br J Cancer, 100, 684, 10.1038/sj.bjc.6604909 Haverkamp, 2000, The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a Policy Conference of the European Society of Cardiology, Cardiovasc Res, 47, 219, 10.1016/S0008-6363(00)00119-X Sandor, 2002, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms, Clin Cancer Res, 8, 718 Piekarz, 2006, Cardiac studies in patients treated with depsipeptide FK229, in a phase II trial for T-cell lymphoma, Clin Cancer Res, 12, 3762, 10.1158/1078-0432.CCR-05-2095 Highlights of Prescribing Information: Sutent® (sunitinib malate) capsules, oral: Initial U.S Approval 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021938s006s007s008lbl.pdf. Herbst, 2007, Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis, Expert Opin Investig Drugs, 16, 239, 10.1517/13543784.16.2.239 Holden, 2005, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors, Ann Oncol, 16, 1391, 10.1093/annonc/mdi247 Miller, 2005, Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastastic breast cancer, Clin Cancer Res, 11, 3369, 10.1158/1078-0432.CCR-04-1923 Heymach, 2007, Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer, J Clin Oncol, 25, 4270, 10.1200/JCO.2006.10.5122 Kiura, 2008, A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer, J Thorac Oncol, 3, 386, 10.1097/JTO.0b013e318168d228 Kovacs, 2006, A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma – NCIC CTG IND.145, Invest New Drugs, 24, 529, 10.1007/s10637-006-9022-7 Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL, N Engl J Med, 354, 2542, 10.1056/NEJMoa055104 Hazarika, 2008, Tasigna for chronic and accelerated phase Philadelphia chromosome – positive chronic myelogenous leukemia resistant to or intolerant of imatinib, Clin Cancer Res, 14, 5325, 10.1158/1078-0432.CCR-08-0308 Kantarjian, 2007, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance, Blood, 110, 3540, 10.1182/blood-2007-03-080689 le Coutre, 2008, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia, Blood, 111, 1834, 10.1182/blood-2007-04-083196 2006 Dowlati, 2002, A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer, Cancer Res, 62, 3408 Britten, 2001, A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778123 in patients with solid malignancies, Clin Cancer Res, 7, 3894 Sharma, 2000, A phase I and PK study of farnesyl transferase inhibitor L-778, 123 administered as a seven day continuous infusion in combination with paclitaxel, Proc Am Soc Clin Oncol, 19, 185a Carducci, 2006, Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer, J Clin Oncol, 24, 4092, 10.1200/JCO.2005.05.3447 Rademaker-Lakhai, 2007, Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer, Clin Cancer Res, 13, 4474, 10.1158/1078-0432.CCR-06-2912 Scappaticci, 2007, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab, J Natl Cancer Inst, 15, 1232, 10.1093/jnci/djm086 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Cooney, 2004, Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer, Clin Cancer Res, 10, 96, 10.1158/1078-0432.CCR-0364-3 Tolcher, 2003, Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days, Proc Am Soc Clin Oncol, 22 Sessa, 2005, A Pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks, Proc Am Assoc Cancer Res, 46 Hanrahan, 2007, Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma, J Clin Oncol, 25, 4952, 10.1200/JCO.2006.08.0499 Fleissig, 2006, Multidisciplinary teams in cancer care: are they effective in the UK?, Lancet Oncol, 7, 935, 10.1016/S1470-2045(06)70940-8 Forrest, 2005, An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer, Br J Cancer, 93, 977, 10.1038/sj.bjc.6602825